搜尋

file (3)

What We Do

學術發表

首頁學術發表

2025.May.01

ADC

OBI-992, a Novel TROP2 Antibody-Drug Conjugate, Exhibits Distinct Resistance Profiles Compared to other TROP2 Targeting ADCs

Poster

2025.May.01

ADC

OBI-902, a Novel TROP2-Targeted Antibody-Drug Conjugate via GlycOBI® Platform, Has Favorable Pharmacokinetics and Sustained Antitumor Activities in Challenging Solid Tumors

Poster

2025.May.01

Technology

Harnessing the GlycOBI® Enabling Technologies: Next-generation Site-Specific Glycan ADCs with Versatile DAR to Enhance Therapeutic Index

Poster

2025.May.01

Technology

ThiOBI® Platform, a Novel Hydrophilic Linker for Irreversible Cysteine-selective Biomolecular Conjugation, Demonstrated Potent and Durable Antitumor Activities in Various Animal Models

Poster

2025.Mar.14

ADC

Preclinical Evaluation of a Novel Antibody-Drug Conjugate OBI-992 for Cancer Therapy

Article

2024.Dec.04

ADC

OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models

Article

2024.Sep.23

Vaccine

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

Article

2024.Aug.20

Technology

High-Efficiency Homogeneous ADC Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism

Poster

2024.May.29

Vaccine

Positive associations of active immune therapy OBI-833/OBI-821 induced immune responses with clinical outcomes in patients with non-small cell lung cancer

Abstract

2024.May.29

Others

Novel TROP2-targeted CAR T cells with high specificity and sustained efficacy for solid tumors in animal models

Abstract